Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

PTCT holding history

PTC Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

PTCT overviewAll 13F holders of PTCTFull Q2 2026 holdings

Shares (Q2 2026)
262,426
Value
$21.4M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of PTCT by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026262,426$21.4M<0.1%−1,102,342−80.8%ReducedHolders
Q1 20261,364,768$93.0M<0.1%+400,110+41.5%AddedHolders
Q4 2025964,658$73.3M<0.1%+512,449+113.3%AddedHolders
Q3 2025452,209$27.8M<0.1%−126,741−21.9%ReducedHolders
Q2 2025578,950$28.3M<0.1%−690,697−54.4%ReducedHolders
Q1 20251,269,647$64.7M<0.1%+198,596+18.5%AddedHolders
Q4 20241,071,051$48.3M<0.1%+905,980+548.8%AddedHolders
Q3 2024165,071$6.12M<0.1%+28,310+20.7%AddedHolders
Q2 2024136,761$4.18M<0.1%−88,699−39.3%ReducedHolders
Q1 2024225,460$6.56M<0.1%−63,288−21.9%ReducedHolders
Q4 2023288,748$7.96M<0.1%+210,883+270.8%AddedHolders
Q3 202377,865$1.74M<0.1%−14,186−15.4%ReducedHolders
Q2 202392,051$3.74M<0.1%+15,229+19.8%AddedHolders
Q1 202376,822$3.72M<0.1%−32,046−29.4%ReducedHolders
Q4 2022108,868$4.16M<0.1%+78,107+253.9%AddedHolders
Q3 202230,761$1.54M<0.1%−27,031−46.8%ReducedHolders
Q2 202257,792$2.31M<0.1%−84,177−59.3%ReducedHolders
Q1 2022141,969$5.30M<0.1%+12,297+9.5%AddedHolders
Q4 2021129,672$5.16M<0.1%+66,850+106.4%AddedHolders
Q3 202162,822$2.34M<0.1%+62,729+67,450.5%AddedHolders
Q2 202193$4.00K<0.1%−32,879−99.7%ReducedHolders
Q1 202132,972$1.56M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.